STOCK TITAN

Hancock Health Expands Robot Specimen Delivery to Parkway Building, Adding Scheduled and On-Demand Runs to the Lab

The robot will return to its existing on-demand route after each Parkway run, leaving current transport routes unchanged.

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags

Arrive AI (NASDAQ:ARAI) is expanding its autonomous specimen delivery system at Hancock Health by adding an Arrive Point at the Parkway Building.

Parkway staff currently carry specimens to Hancock Regional Hospital's laboratory manually, typically two to three times daily. Under the planned expansion, an existing autonomous ground robot will make four to five scheduled pickups daily, with on-demand runs available for time-sensitive specimens. Arrive AI says the change is designed to bring smaller batches to the laboratory more often and sooner. The company is providing installation, staff training and go-live support; its existing Hancock specimen transport system has operated since August 2025.

Loading...
Loading translation...

Key Figures

Scheduled Parkway pickup runs: 4 to 5 runs per day Current manual transport frequency: 2 to 3 times a day
Scheduled Parkway pickup runs
4 to 5 runs per day
Planned service to the laboratory
Current manual transport frequency
2 to 3 times a day
Typical Parkway specimen transport in large batches

Key Terms

autonomous mobile robots (AMRs), autonomous vehicles (AVs), phlebotomy, chain of custody
4 terms
autonomous mobile robots (AMRs) technical
"drones, autonomous mobile robots (AMRs), autonomous vehicles (AVs)"
Autonomous mobile robots (AMRs) are self-guided machines that perform tasks such as moving goods, inspecting facilities, or delivering supplies by navigating spaces using onboard sensors and software instead of a human driver. They matter to investors because they can lower labor costs, speed operations and reduce errors—similar to a self-driving vehicle for warehouses and hospitals—so adoption can change a company’s capital spending, productivity and profit outlook.
autonomous vehicles (AVs) technical
"autonomous mobile robots (AMRs), autonomous vehicles (AVs) and human couriers"
Autonomous vehicles (AVs) are cars or trucks that can operate and navigate without human drivers, using sensors and computer systems to understand their surroundings. They have the potential to transform transportation by increasing safety, reducing traffic congestion, and lowering costs. For investors, AVs represent a significant technological shift that could reshape industries such as automotive, insurance, and logistics.
phlebotomy medical
"specimens from the phlebotomy service can reach the Hancock Regional Hospital laboratory"
Phlebotomy is the medical procedure of drawing blood from a vein, usually for tests, donation, or to relieve excess blood in certain conditions. For investors, it matters because the volume, cost and regulation of blood draws drive revenue and operational demand at clinics, labs and hospitals—think of it like a routine sampling system that provides the raw material for diagnostics and treatments, so changes affect service demand and margins.
chain of custody technical
"with chain of custody built into each handoff"
"Chain of custody" is the process of keeping a clear and documented record of how physical or digital evidence is handled, from collection to final use. It ensures that the evidence remains unaltered and trustworthy, much like tracking a package from sender to recipient to confirm it hasn't been tampered with. This is important for investors because it helps verify the integrity and accuracy of information or assets being evaluated.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

INDIANAPOLIS, IN / ACCESS Newswire / November 9, 2026 / Arrive AI (NASDAQ:ARAI), a physical AI and autonomous logistics infrastructure company enabling drones, autonomous mobile robots (AMRs), autonomous vehicles (AVs) and human couriers to securely exchange goods, today announced the next phase of its work with Hancock Health in Greenfield, Indiana. An Arrive Point™ is being added at the Parkway Building, outside the hospital, so that specimens from the phlebotomy service can reach the Hancock Regional Hospital laboratory more often.

Since August 2025, Arrive AI's autonomous specimen transport system has carried specimens from an Arrive Point™ at the Hancock Health Sue Ann Wortman Cancer Center to the laboratory inside Hancock Regional Hospital.

Parkway phlebotomy staff currently transport specimens to the laboratory manually in large batches, typically two to three times a day. The center serves walk-in patients, with about 60 patients a day including a morning rush from 8:00 to 10:00 a.m. that leads to a large batches of specimens that need to be analyzed.

With the new Arrive Point™, Parkway staff will place specimens in the unit, and an autonomous ground robot already operating at Hancock will make four to five scheduled pickup runs each day to carry them to the laboratory. The robot returns to its existing on-demand route after each Parkway run, so current transport routes continue as they do today. The robot will also be available for on-demand runs for time-sensitive specimens, such as stat orders.

The laboratory will receive arrival notifications for Parkway deliveries, as it does for the existing route. Arrive AI is providing installation, staff training, and go-live support.

The change is designed to give the laboratory smaller groups of specimens more often instead of large batches, and to help specimens drawn at Parkway reach the lab sooner.

The Arrive Point™ is a secure delivery endpoint where a package can be dropped off or picked up without anyone waiting on the other end, with chain of custody built into each handoff.

"Our lab team does its best work when specimens arrive in manageable groups throughout the day," said Matt Browning, COO, Hancock Health. "Adding Parkway to this system is designed to get those specimens to the lab sooner and more steadily. This will help us further improve patient care."

"Hancock Health has been running an Arrive Point network system since August 2025, and this next step builds directly on what their team has learned," said Dan O'Toole, Founder, Chairman and CEO of Arrive AI. "Moving specimens in smaller groups, more often, is the kind of everyday work autonomous secure handoff is designed to address. We appreciate our continued collaboration with Hancock team as we collectively expand how we can add value and efficiency to this important work."

About Hancock Health

Hancock Health is an independent, full-service healthcare network serving East Central Indiana. A proud member of the Mayo Clinic Care Network, Hancock Health has been nationally recognized for outstanding clinical outcomes by The Leapfrog Group and the Lown Institute. The network includes Hancock Regional Hospital and Hancock Physician Network; and more than 30 other facilities, such as: the Green Family Foundation Behavioral Health Center, wellness centers, women's clinics, family practices, the Sue Ann Wortman Cancer Center, and Gateway Hancock Health. In addition to our membership in the Mayo Clinic Care Network, we offer enhanced patient care through our relationships with Suburban Health Organization, Peyton Manning Children's Hospital, and the Ascension St. Vincent Heart Center.

About Arrive AI

Arrive AI (NASDAQ:ARAI) is building the infrastructure for autonomous logistics through a network of intelligent delivery endpoints that enable secure, asynchronous exchange of goods. The company's platform supports drones, ground robotics, and human couriers, solving the "last inch of the last-mile" challenge across logistics, healthcare, and enterprise delivery.

Forward-Looking Statements

This news release and statements of Arrive AI's management in connection with this release or related events may contain "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Forward-looking statements relate to future events and expected business and financial performance and often include words such as "expects," "anticipates," "intends," "plans," "believes," "potential," "will," "should," "could," "would," "optimistic," or "may," and similar expressions. These statements are based on information available as of the date of this release and reflect management's current views and assumptions. They are not guarantees of future performance and involve known and unknown risks, uncertainties, and other factors that may be beyond the company's control. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this release. Potential investors should review Arrive AI's Registration Statement and other filings, including risk factors, available at the U.S. Securities and Exchange Commission website at www.sec.gov. Arrive AI undertakes no obligation to update forward-looking statements to reflect events or circumstances after the date of this release, except as required by law.

Media Contact
Tasha Jones, Marketing Communications Manager, Arrive AI, media@arriveai.com

Investor Contact
Alliance Advisors IR, ARAI.IR@allianceadvisors.com

SOURCE: Arrive AI, Inc.



View the original press release on ACCESS Newswire

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is Arrive AI adding at Hancock Health's Parkway Building?

Arrive AI is adding an Arrive Point for autonomous specimen deliveries to Hancock Regional Hospital's laboratory. An existing ground robot will make four to five scheduled pickups daily and will also be available for on-demand transport of time-sensitive specimens.

Keep reading